Cempra, Inc. to Present at Three Investor Conferences

By GlobeNewswire,  May 08, 2014, 04:00:00 PM EDT


CHAPEL HILL, N.C., May 8, 2014 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP) today announced that Prabhavathi Fernandes, Ph.D., chief executive officer of Cempra, will present at three upcoming investor conferences.

  • Bank of America Merrill Lynch 2014 Health Care Conference at 11:20 a.m. PDT, Thursday, May 15, at the Encore at the Wynn hotel in Las Vegas
  • UBS Global Healthcare Conference at 11:30 a.m. EDT, Wednesday, May 21, at the Sheraton New York hotel in New York City
  • Jefferies 2014 Global Healthcare Conference at 11 a.m. EDT, Tuesday, June 3, at the Grand Hyatt hotel in New York City

Live webcasts of the presentations at the Bank of America Merrill Lynch 2014 Health Care Conference and Jefferies 2014 Global Healthcare Conference will be available on Cempra's website at www.cempra.com. The presentations will be archived on the company's website and available for 90 days.

About Cempra, Inc.

Founded in 2006, Cempra, Inc. is a late clinical-stage pharmaceutical company focused on developing antibiotics to treat critical bacterial infections in patients in both acute and primary care settings. Cempra's two lead product candidates are currently in advanced clinical development. Solithromycin (CEM-101) is in two Phase 3 clinical trials for community-acquired bacterial pneumonia (CABP) and is licensed to strategic commercial partner Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation, for certain exclusive rights in Japan. TAKSTA™ (CEM-102) is Cempra's second product candidate currently in a Phase 2 clinical trial for prosthetic joint infections. TAKSTA was recently granted orphan drug designation for this indication. Both product candidates seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. The company has also synthesized novel macrolides for non-antibiotic uses such as the treatment of gastric motility disorders. Additional information about Cempra can be found at www.cempra.com.

CONTACT: Investor and Media Contacts:
         Robert E. Flamm, Ph.D.
         Russo Partners, LLC
         (212) 845-4226
         Robert.flamm@russopartnersllc.com

         Andreas Marathovouniotis
         Russo Partners, LLC
         (212) 845-4235
         Andreas.marathis@russopartnersllc.com
Source: Cempra, Inc.

This article appears in: News Headlines

Referenced Stocks: CEMP


Latest News Video





Most Active by Volume

Company Last Sale Change Net / %
RAD $ 6.79 0.26 ▼ 3.69%
SIRI $ 3.39 0.05 ▼ 1.45%
AAPL $ 98.691 1.02 ▲ 1.04%
FB $ 75.18 0.01 ▼ 0.01%
BAC $ 15.4815 0.11 ▼ 0.70%
FDO $ 75.52 14.86 ▲ 24.50%
DLTR $ 56.10 1.88 ▲ 3.47%
GE $ 25.62 0.17 ▼ 0.66%

As of 7/28/2014, 01:53 PM